Association of the Endotoxin Antagonist E5564 with High-density Lipoproteins in Vitro: Dependence on Low-density and Triglyceride-rich Lipoprotein Concentrations

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2003 Aug 26

PMID 12936976

Citations 7

Authors

Kishor M Wasan

Olena Sivak

Richard A Cote

Aaron I MacInnes

Kathy D Boulanger

Melvyn Lynn

William J Christ

Lynn D Hawkins

Daniel P Rossignol

Affiliations

Soon will be listed here.

Abstract

The objective of this study was to determine the distribution profile of the novel endotoxin antagonist E5564 in plasma obtained from fasted human subjects with various lipid concentrations. Radiolabeled E5564 at 1 microM was incubated in fasted plasma from seven human subjects with various total cholesterol (TC) and triglyceride (TG) concentrations for 0.5 to 6 h at 37 degrees C. Following these incubations, plasma samples were separated into their lipoprotein and lipoprotein-deficient fractions by ultracentrifugation and were assayed for E5564 radioactivity. TC, TG, and protein concentrations in each fraction were determined by enzymatic assays. Lipoprotein surface charge within control and phosphatidylinositol-treated plasma and E5564's influence on cholesteryl ester transfer protein (CETP) transfer activity were also determined. We observed that the majority of E5564 was recovered in the high-density lipoprotein (HDL) fraction. We further observed that incubation in plasma with increased levels of TG-rich lipoprotein (TRL) lipid (TC and TG) concentrations resulted in a significant increase in the percentage of E5564 recovered in the TRL fraction. In further experiments, E5564 was preincubated in human TRL. Then, these mixtures were incubated in hypolipidemic human plasma for 0.5 and 6 h at 37 degrees C. Preincubation of E5564 in purified TRL prior to incubation in human plasma resulted in a significant decrease in the percentage of drug recovered in the HDL fraction and an increase in the percentage of drug recovered in the TRL and low-density lipoprotein fractions. These findings suggest that the majority of the drug binds to HDLs. Preincubation of E5564 in TRL prior to incubation in normolipidemic plasma significantly decreased the percentage of drug recovered in the HDL fraction. Modifications to the lipoprotein negative charge did not alter the E5564 concentration in the HDL fraction. In addition, E5564 does not influence CETP-mediated transfer activity. Information from these studies could be used to help identify the possible components of lipoproteins which influence the interaction of E5564 with specific lipoprotein particles.

Citing Articles

MD-2 as the target of a novel small molecule, L6H21, in the attenuation of LPS-induced inflammatory response and sepsis.

Wang Y, Shan X, Chen G, Jiang L, Wang Z, Fang Q Br J Pharmacol. 2015; 172(17):4391-405.

PMID: 26076332 PMC: 4556476. DOI: 10.1111/bph.13221.

TLR4 inhibition impairs bacterial clearance in a therapeutic setting in murine abdominal sepsis.

van Lieshout M, van der Poll T, Vant Veer C Inflamm Res. 2014; 63(11):927-33.

PMID: 25118783 DOI: 10.1007/s00011-014-0766-9.

Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.

Barochia A, Solomon S, Cui X, Natanson C, Eichacker P Expert Opin Drug Metab Toxicol. 2011; 7(4):479-94.

PMID: 21323610 PMC: 3065179. DOI: 10.1517/17425255.2011.558190.

Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases.

Leon C, Tory R, Jia J, Sivak O, Wasan K Pharm Res. 2008; 25(8):1751-61.

PMID: 18493843 PMC: 2469272. DOI: 10.1007/s11095-008-9571-x.

Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits.

Wasan K, Risovic V, Sivak O, Lee S, Mason D, Chiklis G Pharm Res. 2007; 25(1):176-82.

PMID: 17849177 DOI: 10.1007/s11095-007-9428-8.

References

Kennedy A, Wasan K . Preferential distribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content. J Pharm Sci. 1999; 88(11):1149-55. DOI: 10.1021/js990101z. View

Wasan K, Strobel F, Parrott S, Lynn M, Christ W, Hawkins L . Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels. Antimicrob Agents Chemother. 1999; 43(10):2562-4. PMC: 89522. DOI: 10.1128/AAC.43.10.2562. View

Stamler C, Breznan D, Neville T, Viau F, Camlioglu E, Sparks D . Phosphatidylinositol promotes cholesterol transport in vivo. J Lipid Res. 2000; 41(8):1214-21. View

Burstein M, Scholnick H, Morfin R . Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970; 11(6):583-95. View

Pattnaik N, ZILVERSMIT D . Interaction of cholesteryl ester exchange protein with human plasma lipoproteins and phospholipid vesicles. J Biol Chem. 1979; 254(8):2782-6. View

MORTON R, ZILVERSMIT D . Purification and characterization of lipid transfer protein(s) from human lipoprotein-deficient plasma. J Lipid Res. 1982; 23(7):1058-67. View

Lemaire M, Tillement J . Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol. 1982; 34(11):715-8. DOI: 10.1111/j.2042-7158.1982.tb06206.x. View

Groot P, Scheek L, Havekes L, van Noort W, vant Hooft F . A one-step separation of human serum high density lipoproteins 2 and 3 by rate-zonal density gradient ultracentrifugation in a swinging bucket rotor. J Lipid Res. 1982; 23(9):1342-53. View

Vitols S, Gahrton G, Bjorkholm M, Peterson C . Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: evidence from studies in patients with leukaemia. Lancet. 1985; 2(8465):1150-4. DOI: 10.1016/s0140-6736(85)92679-0. View

10.

Alvarez C, Ramos A . Lipids, lipoproteins, and apoproteins in serum during infection. Clin Chem. 1986; 32(1 Pt 1):142-5. View

11.

Lemaire M, Pardridge W, Chaudhuri G . Influence of blood components on the tissue uptake indices of cyclosporin in rats. J Pharmacol Exp Ther. 1988; 244(2):740-3. View

12.

Bone R . Gram-negative sepsis. Background, clinical features, and intervention. Chest. 1991; 100(3):802-8. DOI: 10.1378/chest.100.3.802. View

13.

Arnadottir M, Thysell H, Nilsson-Ehle P . Lipoprotein levels and post-heparin lipase activities in kidney transplant recipients: ciclosporin- versus non-ciclosporin-treated patients. Am J Nephrol. 1991; 11(5):391-6. DOI: 10.1159/000168344. View

14.

Grunfeld C, Pang M, Doerrler W, Shigenaga J, Jensen P, Feingold K . Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992; 74(5):1045-52. DOI: 10.1210/jcem.74.5.1373735. View

15.

Parrillo J . Pathogenetic mechanisms of septic shock. N Engl J Med. 1993; 328(20):1471-7. DOI: 10.1056/NEJM199305203282008. View

16.

Feingold K, Krauss R, Pang M, Doerrler W, Jensen P, Grunfeld C . The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab. 1993; 76(6):1423-7. DOI: 10.1210/jcem.76.6.8501146. View

17.

Umeki S . Decreases in serum cholesterol levels in advanced lung cancer. Respiration. 1993; 60(3):178-81. DOI: 10.1159/000196195. View

18.

Gardier A, Mathe D, Guedeney X, Barre J, Benvenutti C, Navarro N . Effects of plasma lipid levels on blood distribution and pharmacokinetics of cyclosporin A. Ther Drug Monit. 1993; 15(4):274-80. DOI: 10.1097/00007691-199308000-00003. View

19.

Wasan K, Grossie Jr V, Lopez-Berestein G . Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion. Antimicrob Agents Chemother. 1994; 38(9):2224-6. PMC: 284720. DOI: 10.1128/AAC.38.9.2224. View

20.

Christ W, ASANO O, Robidoux A, Perez M, Wang Y, Dubuc G . E5531, a pure endotoxin antagonist of high potency. Science. 1995; 268(5207):80-3. DOI: 10.1126/science.7701344. View